Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted ETD001 designation as an orphan medicinal product for the treatment of cystic fibrosis. This follows the announcement earlier this year of a positive Phase 2 clinical trial outcome of ETD001, an investigational inhaled epithelial sodium channel (ENaC) blocker, designed to increase lung function by improving mucus clearance and reducing airway obstruction.

The EMA COMP opinion concluded that ETD001 meets the orphan-designation criteria, recognizing disease rarity and the potential for ETD001 to provide clinically relevant benefit, including for people who are not eligible for CFTR modulator therapy. The recommendation was supported by clinical data from the Phase 2 ET-ENAC-03 study, which were indicative of lung function improvement. Orphan medicine designation offers a range of benefits, including market exclusivity once the therapy is on the market.

Orphan drug designation represents an important regulatory milestone for the ETD001 program and for Enterprise Therapeutics. The decision by the EMA reflects the continued need for additional treatment options for people with cystic fibrosis, particularly those who are not able to benefit from CFTR modulators. We look forward to continuing the development of ETD001 in CF as well as other mucus congestion related respiratory diseases."

Dr. John Ford, CEO, Enterprise Therapeutics

Annabella Amatulli, Head of Regulatory Affairs, Enterprise Therapeutics, added: "Our regulatory strategy supports our global development plan for ETD001, aligned with our goal to provide improved therapeutic options for people with cystic fibrosis. The EMA's orphan drug designation further validates the strength of the program's scientific rationale and outcomes of the Phase 2 clinical trial."

Cystic fibrosis is estimated to affect over 100,000 people worldwide, and leads to reduced life expectancy. Failed mucociliary clearance and mucus congestion in the lungs leads to cycles of infection and inflammation and an ongoing decline in lung function.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Enterprise Therapeutics Ltd. (2026, November 17). Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001. News-Medical. Retrieved on November 17, 2026 from https://www.news-medical.net/news/20261117/Enterprise-Therapeutics-granted-EMA-orphan-medicinal-product-designation-for-novel-cystic-fibrosis-therapy-ETD001.aspx.

  • MLA

    Enterprise Therapeutics Ltd. "Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001". News-Medical. 17 November 2026. <https://www.news-medical.net/news/20261117/Enterprise-Therapeutics-granted-EMA-orphan-medicinal-product-designation-for-novel-cystic-fibrosis-therapy-ETD001.aspx>.

  • Chicago

    Enterprise Therapeutics Ltd. "Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001". News-Medical. https://www.news-medical.net/news/20261117/Enterprise-Therapeutics-granted-EMA-orphan-medicinal-product-designation-for-novel-cystic-fibrosis-therapy-ETD001.aspx. (accessed November 17, 2026).

  • Harvard

    Enterprise Therapeutics Ltd. 2026. Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001. News-Medical, viewed 17 November 2026, https://www.news-medical.net/news/20261117/Enterprise-Therapeutics-granted-EMA-orphan-medicinal-product-designation-for-novel-cystic-fibrosis-therapy-ETD001.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Enterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director